结肠癌中奥沙利铂毒性和耐药性相关基因SNPs的研究进展

被引：9

作者：

姚雨江 ^{[1
]}

谢妮 ^{[2
,3
]}

机构：

[1] 广东医学院病理生理教研室

[2] 深圳大学第一附属医院

[3] 深圳市第二人民医院生物标本库

来源：

临床与病理杂志 | 2014年 / 34卷 / 06期

关键词：

SNPs; 奥沙利铂; 结肠癌; 耐药性; 毒性;

D O I：

暂无

中图分类号：

R735.35 [];

学科分类号：

摘要：

化疗在结肠癌的治疗中仍起着举足轻重的作用,尤其是在术后辅助治疗和转移癌症治疗中。目前,化疗多采用联合配伍的方案,奥沙利铂被采用作为转移性结肠癌的联合用药之一,使得结肠癌的副毒作用和药效得到相对改善。但仍不可避免有副作用和耐药性的产生,且具有个体差异性。这与许多原因有关,其中病人的遗传差异起了举足轻重的作用。本综述通过回顾最近关于结肠癌中奥沙利铂为基础的联合用药毒性和耐药性相关基因的单核苷酸多态性(single nucleotide polymorphisms,SNPs)及其作用机制的研究,为进一步科学研究和临床个体化用药提供依据。

引用

页码：797 / 807

页数：11

共 31 条

[1]

XRCC1 and XPD genetic polymorphisms and clinical outcomes of gastric cancer patients treated with oxaliplatin-based chemotherapy: a meta-analysis [J].

Zhang, Xin ;

Jiang, Li-Peng ;

Yin, Yu ;

Wang, Ya-Di .

TUMOR BIOLOGY, 2014, 35 (06) :5637-5645

[2]

Role of cyclin polymorphisms in predicting outcome of 5-fluorouracil-based chemotherapy in colorectal cancer: one piece in a complex puzzle [J].

LaBonte, Melissa J. ;

Lenz, Heinz-Josef .

PHARMACOGENOMICS, 2013, 14 (14) :1671-1674

[3]

Current strategies to minimize toxicity of oxaliplatin: selection of pharmacogenomic panel tests [J].

Di Francia, Raffaele ;

Siesto, Raffaella Stefania ;

Valente, Daniela ;

Del Buono, Andrea ;

Pugliese, Sergio ;

Cecere, Sabrina ;

Cavaliere, Carla ;

Nasti, Guglielmo ;

Facchini, Gaetano ;

Berretta, Massimiliano .

ANTI-CANCER DRUGS, 2013, 24 (10) :1069-1078

[4]

Excision Repair Cross-Complementation group 1 ( ERCC1 ) C118T SNP does not affect cellular response to oxaliplatin.[J].Lieke H. van Huis-Tanja;Dina M. Kweekel;Xiaobo Lu;Kees Franken;Miriam Koopman;Hans Gelderblom;Ninja F. Antonini;Cornelis J.A. Punt;Henk-Jan Guchelaar;Tahar van der Straaten.Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis.2014,

[5]

Voltage-Gated Sodium Channel Polymorphisms Play a Pivotal Role in the Development of Oxaliplatin-Induced Peripheral Neurotoxicity Results From a Prospective Multicenter Study [J].

Argyriou, Andreas A. ;

Cavaletti, Guido ;

Antonacopoulou, Anna ;

Genazzani, Armando A. ;

Briani, Chiara ;

Bruna, Jordi ;

Terrazzino, Salvatore ;

Velasco, Roser ;

Alberti, Paola ;

Campagnolo, Marta ;

Lonardi, Sara ;

Cortinovis, Diego ;

Cazzaniga, Marina ;

Santos, Cristina ;

Psaromyalou, Aikaterini ;

Angelopoulou, Aikaterini ;

Kalofonos, Haralabos P. .

CANCER, 2013, 119 (19) :3570-3577

[6]

A Phase II Clinical Study of mFOLFOX6 Plus Bevacizumab as First-line Therapy for Japanese Advanced/Recurrent Colorectal Cancer Patients [J].

Nishina, Tomohiro ;

Takano, Yoshinao ;

Denda, Tadamichi ;

Yasui, Hisateru ;

Takeda, Koji ;

Ura, Takashi ;

Esaki, Taito ;

Okuyama, Yusuke ;

Kondo, Ken ;

Takahashi, Yasuo ;

Sugiyama, Yasuyuki ;

Muro, Kei .

JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2013, 43 (11) :1080-1086

[7]

Multidrug resistance protein 2 genetic polymorphism and colorectal cancer recurrence in patients receiving adjuvant FOLFOX-4 chemotherapy [J].

Mirakhorli, Mojgan ;

Rahman, Sabariah Abdul ;

Abdullah, Syahrilnizam ;

Vakili, Masoud ;

Rozafzon, Reza ;

Khoshzaban, Ahad .

MOLECULAR MEDICINE REPORTS, 2013, 7 (02) :613-617

[8]

Polymorphisms of GSTP1; ERCC2 and TS‑3'UTR are associated with the clinicaloutcome of mFOLFOX6 in colorectal cancer patients.[J].Kensuke Kumamoto;Keiichiro Ishibashi;Norimichi Okada;Yusuke Tajima;Kouki Kuwabara;Yoichi Kumagai;Hiroyuki Baba;Norihiro Haga;Hideyuki Ishida.Oncology Letters.2013, 3

[9]

Differential toxicity biomarkers for irinotecan- and oxaliplatin-containing chemotherapy in colorectal cancer [J].

Cortejoso, Lucia ;

Garcia, Maria I. ;

Garcia-Alfonso, Pilar ;

Gonzalez-Haba, Eva ;

Escolar, Fernando ;

Sanjurjo, Maria ;

Lopez-Fernandez, Luis A. .

CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2013, 71 (06) :1463-1472

[10]

Genetic Polymorphism of XRCC1 Correlated with Response to Oxaliplatin-based Chemotherapy in Advanced Colorectal Cancer.[J].Hongying Lv;Qicai Li;Wengsheng Qiu;Jinyu Xiang;Hongjun Wei;Hua Liang;Aihua Sui;Jun Liang.Cancer Investigation.2013, 1

← 1 2 3 4 →